Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Brexpiprazole ODT vs Conventional Tablets
NCT02875080Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole in schizophrenia and major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 312 hours, Area Under the Concentration-time Curve From Time Zero to Infinity at 312 hours and 1 more. Started Sep 2016; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02875080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875080.